Bioorganic and Medicinal Chemistry Letters p. 2635 - 2640 (1998)
Update date:2022-08-03
Topics:
Montana, John G.
Buckley, George M.
Cooper, Nicola
Dyke, Hazel J.
Gowers, Lewis
Gregory, Joanna P.
Hellewell, Paul G.
Kendall, Hannah J.
Lowe, Christopher
Maxey, Robert
Miotla, Jadwiga
Naylor, Robert J.
Runcie, Karen A.
Tuladhar, Bishwa
Warneck, Julie B. H.
A series of novel selective phosphodiesterase 4 (PDE4) inhibitors has been developed which displays activity both in vitro and in vivo. These compounds possess good selectivity for the catalytic site of PDE4 over the high affinity Rolipram binding site. In vivo studies demonstrate a reduced propensity to display the emetic side effects which are commonly observed with PDE4 inhibitors.
View MoreShanghai Mio Chemical Co., Ltd
Contact:0086 21- 64401188-622
Address:16 Floor NO.2 Jiefang Building, No. 4855 Dushi Road, 201100 Shanghai, P.R.China
Contact:+86-571-86217390
Address:No.567 Dengcai Street,Sandun,Westlake District,Hangzhou310030,Zhejiang,China.
Tianjin Bright Future Technology Co., Ltd
Contact:0086-22-58016666
Address:NO.136 DongTeng Lake Street Tianjin Economic and Technology Development Area,Tainjin,China
Shanghai Pengkai Chemical Co.,Ltd
Contact:+86-21-60526671
Address:No.4226 Duzhuang Rd Minhang District Shanghai China
Hubei Lansun Biochemical Pharmaceutical Co., Ltd
Contact:714-6395977
Address:No. 81 Pengcheng Avenue, economic and technological development zone, Huangshi City, Hubei Province,China
Doi:10.1021/jm301217c
(2012)Doi:10.1021/ic300872m
(2012)Doi:10.1021/jm301212u
(2012)Doi:10.1007/BF00901092
(1967)Doi:10.1039/c2ob26103k
(2012)Doi:10.1016/j.bmcl.2012.08.089
(2012)
